Bridgebio Oncology Therapeutics, Inc. (BBOT)
2.62
-0.08
(-2.96%)
USD |
NASDAQ |
Oct 30, 16:00
2.64
+0.02
(+0.76%)
After-Hours: 20:00
Bridgebio Oncology Therapeutics Total Liabilities (Quarterly) : 53.59M for June 30, 2026
Total Liabilities (Quarterly) Chart
Historical Total Liabilities (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 53.59M |
| March 31, 2026 | 45.37M |
| December 31, 2025 | 37.98M |
| September 30, 2025 | 38.09M |
| June 30, 2025 | 8.149M |
| March 31, 2025 | 7.391M |
| Date | Value |
|---|---|
| December 31, 2024 | 19.59M |
| September 30, 2024 | 5.647M |
| June 30, 2024 | 5.599M |
| March 31, 2024 | 5.543M |
| December 31, 2023 | 0.3965M |
| December 31, 2022 | 0.1665M |
Total Liabilities Definition
Liabilities are a main portion of the balance sheet of a company that measure outstanding payables/obligations. A few examples of liabilties of a company include accounts payable, current debt, and capital lease obligations. From an accounting perspective, the balance sheet equation is Liabilties = Assets - Shareholder's Equity.
Total Liabilities (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Total Liabilities (Quarterly) Benchmarks
| Korsana Biosciences, Inc. | 1.843M |
| IRulya Therapeutics, Inc. | 15.51M |
| PepGen Inc. | 21.86M |
| Q32 Bio, Inc. | 9.962M |
| Arrowhead Pharmaceuticals, Inc. | 1.646B |
Total Liabilities (Quarterly) Related Metrics
| Total Assets (Quarterly) | 376.71M |
| Shareholders Equity (Quarterly) | 323.11M |
| Debt to Equity Ratio | 0.0078 |
| Current Ratio | 4.694 |
| Net Debt Paydown Yield | -0.08% |